Boston Scientific cuts annual forecast, shares rise on reset

CellComplete biosynthesis of the anticancer cephalotaxinone and homoerythratine

Endpoints NewsAmgen and the FDA want two different outcomes for Tavneos. What will patients do?

Endpoints NewsEli Lilly invests in startup Abridge for clinical trial recruitment

BioWorldMoney raised by biopharma

BioWorldBiopharma money raised: Jan. 1-June 11, 2026

FierceBiotech‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing

BioWorldTakeda’s zasocitinib bests Sotyktu in phase III psoriasis trial

Endpoints NewsEnliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study

Endpoints NewsBiopharma's pay oddities of 2025: Executive perks and eccentricities

FierceBiotechGuardant Health nabs FDA test approval to find patients for Boehringer’s new cancer drug

FierceBiotechIpsen R&D chief on pipeline discipline, partnerships and 2026 milestones

PLoS BiologyIntAct-U-ExM enables super-resolution imaging of isoform-specific actin networks across species